Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Author

G. Shapiro

h-index 16 View on Semantic Scholar

We have 8 of 49 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

A Phase 1 Trial of Low-dose Gemcitabine Combined with ATR Inhibitor Elimusertib for Advanced Solid Tumors.

PURPOSE Preclinical data suggest that the anti-cancer efficacy of ATR inhibitors can be synergistically enhanced by low-dose gemcitabine. To test the clinical feasibility of this regimen, we conducted a phase 1 trial of low-dose gemcitabine combined with the ATR inhibitor elimusertib (BAY1895344). PATIENTS AND METHOD...

T. Jayakrishnan, Rebecca L. Porter, Alice P. Chen et al. · 0 citations
Sep 2026

Abstract A127: Targeting replication stress in pancreatic cancer: results of a phase 1b trial of azenosertib and gemcitabine in second line pancreatic cancer after progression on FOLFIRINOX

The combination of azenosertib and gemcitabine was associated with substantial myelosuppression in patients with metastatic PDAC previously treated with FOLFIRINOX, limiting further clinical evaluation of this dosing strategy.

B. Huffman, Haeseong Park, N. Jackson et al. · 0 citations
Review Open access Oct 2026

Next-generation CDK inhibitors in HR+/HER2– breast cancer

Cell-cycle dysregulation is a central driver of breast cancer progression and a major therapeutic vulnerability, particularly in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) disease. The clinical success of cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine t...

D. Seriak, J. Kim, G. Shapiro et al. · 0 citations
Open access Aug 2026

A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

The combination of the ATR inhibitor berzosertib with carboplatin demonstrated a lower ORR and more frequent ≥ grade 3 TrAEs compared with docetaxel + carboplatin in this heavily pretreated, biomarker-unselected mCRPC population.

A. Choudhury, C. Zhong, Wan-Ling Xie et al. · 0 citations
Review Open access Oct 2026

Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions

Homologous recombination repair deficiency (HRD) occurs in approximately 10% of breast tumors and represents a major targetable vulnerability across multiple cancer types. Impairment of the homologous recombination DNA repair pathway — arising through somatic and germline mutations in homologous recombination repair ge...

Charlotte S. Walmsley, Adela Rodríguez, P. Konstantinopoulos et al. · 0 citations
Open access Oct 2026

PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer

Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPis) have improved outcomes of BRCA-associated breast cancer; however, treatment-related toxicity remains a major clinical challenge. Currently approved PARPis broadly inhibit multiple members of the PARP protein family. However, preclinical studies sugges...

Adam Nelson, Kelly F. Zheng, C. Wanderley et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.